EATONTOWN, NJ, November 8, 2022 – Clinilabs Drug Development Corporation (“Clinilabs”), a leading global, full-service CNS CRO, today announced that Dr. Jeff Mulchahey has joined the company as Chief Development Officer (CDO). Dr. Mulchahey will continue to expand Clinilabs’ presence as a global leader in the management of phase 2 and 3 CNS clinical trials, [...]
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to [...]
EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”). [...]
April 21, 2022 12:00 UTC TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has partnered with Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company’s Phase 1/2a clinical trial of [...]
Pharmaceutical companies have used experimental models of transient insomnia to assess the sleep-promoting effects of investigational drugs for over 40 years. These models have included the "first-night effect" model, a parallel-group design that assessed drug effects when sleep was recorded in normal, healthy subjects who slept in a new or novel environment for the [...]
Clinilabs and the DTRA Aim to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research June 7, 2021 – Clinilabs Drug Development Corporation joins a historic alliance of over one hundred life science and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized [...]
Clinilabs congratulates Larimar Therapeutics Inc. on their Topline Phase 1 Clinical Trial Data in patients with Friedreich’s Ataxia! We are proud to have been part of this clinical trial and to have worked with this partner who is dedicated to bringing life changing treatments to patients with this rare disease. To learn more about [...]
2020 will go down as a miserable year, but beyond the heartache, some developments may represent bright spots that light the way to the future. One of these is the growth of Decentralized Clinical Trials (DCTs). DCTs are virtual trials that integrate remote assessments with modern digital health technologies, including remote rating apps, wearable monitoring [...]
T3D Therapeutics, Inc. (“T3D Therapeutics” or the “Company”), a biopharmaceutical company specializing in the development of ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease and other neurodegenerative diseases, announced it has engaged Clinilabs Drug Development Corporation (“Clinilabs”) as the contract research organization (“CRO”) for its upcoming phase 2 trial of T3D-959 named the PIONEER [...]
We know how unsettling these times are for everyone - especially for those of us in the clinical trials space who need guidance on how to manage the demands of ongoing and future CNS clinical trials. Despite these challenges, we know now more than ever, the importance of the scientific community and the medical [...]
